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Background: Epidemiological characteristics of patients with bloodstream infections (BSI) due to extended-spectrum
β-lactamase producing (ESBL) and carbapenem-resistant (CRE) strains are often similar. Mortality rates for CRE
BSI are 70 %, and mean time to initiation of appropriate therapy is ~5 days. A bedside score was developed to
differentiate CRE-BSIs from ESBL-BSIs, in order to help decrease the time to initiation of appropriate therapy for CRE
and mortality rates.
Findings: Score was developed based of data (2007–2010) abstracted from charts of adult patients from Assaf
Harofeh Medical Center (AHMC, Zeriffin, Israel), and validated on a cohort of patients from Detroit Medical Center
(DMC, MI, USA). A multivariate model for presence of CRE was generated. A clinical prediction score and ROC
curve was derived. 451 patients with ESBL BSIs (285 from AHMC and 166 from DMC) and 74 patients with CRE
BSIs (58 from AHMC and 16 from DMC) were included. The prediction score included chemotherapy in the past
3 months (19 points), presence of foreign invasive devices (10 points), no peripheral vascular disease (10 points),
reduced consciousness or cognition at time of acute illness (9 points), time in hospital prior to BSI ≥ 3 days
(7 points), and age younger than 65 years (6 points). A score of ≥32 to define “high CRE risk” had sensitivity of
59 %, specificity of 76 %, PPV of 34 % and NPV of 90 %.
Conclusions: The score’s 90 % NPV implies it could reduce un-necessary (and toxic) empiric use of anti-CRE
therapeutics, but this should be studied prospectively and on broader populations in order to test its potential role
in reducing mortality.
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the commonest enteric pathogens (e.g. Escherichia coli,
Klebsiella pneumoniae) had become endemic in many re-
gions worldwide [1]. Both extended-spectrum β-lactamase
producing Enterobacteriaceae (ESBL) and carbapenem-
resistant Enterobacteriaceae (CRE) are now frequently en-
countered nosocomial pathogens, but there are multiple
resemblances in their epidemiological features [1, 2]. While
confronted with severely septic patients, in these endemic
facilities, it is often challenging for physicians to tailor the* Correspondence: drormarchaim@gmail.com
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creativecommons.org/publicdomain/zero/1.0/most suitable empiric regimen to patients, when Entero-
bacteriaceae bloodstream infection (BSI) is suspected [3].
Carbapenems are still considered the agents of choice for
ESBL BSIs, but are ineffective (when given alone) against
CRE [3]. Since time to initiation of appropriate therapy is
the strongest modifiable independent predictor for mortal-
ity in severe sepsis [4], physicians need to act fast in order
to impact patients’ outcomes. However, the mean number
of hours to initiation of appropriate therapy for patients
with CRE is 120 ± 23 h, i.e. 5 days [5], mainly due to de-
lays in current routine practices for CRE determination
in microbiology laboratories [1]. Therefore, it is not
surprising that the attributable mortality rate among
patients with CRE BSIs is 70 % [6]. Physicians arearticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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severe invasive infection, i.e. BSI, polymixins are fre-
quently and practically the only remaining appropriate
agents) due to: 1) concerns pertaining to induction of
resistance to the few remaining therapeutic options that
are still available [7], 2) High rate of toxicities associated
with polymixins use, and 3) scant controlled scientific
data, pertaining to polymixins efficacy and pharmaco-
kinetics properties in patients with CRE BSI [8].
An easy to calculate score, with high performance,
based solely on parameters readily available bedside to
attending clinicians, is needed in order to direct pre-
scribers in their management of severely septic patients
in the hospital settings. Prior attempts to develop such a
score by our group, had few limitations, since it was
based on only 16 CRE BSI cases during initial CRE
emergence into the region, when endemicity was not yet
established [9]. Our current study aims were to 1) develop
a different bedside score, based on more cases and from a
‘stable’ endemic CRE region, in order to help physicians
quantify the likelihood for BSI caused by CRE as opposed
to ESBL, and 2) validate the score on a different cohort
of patients from a distinct geographic region, that was
initially studied in our first attempt for score’s develop-
ment [9].
Findings
The Assaf Harofeh Medical Center (AHMC) is an 813-
bed academic tertiary facility in the southern-central
part of Israel. CRE is endemic in this region [1]. Score
validation was executed at the Detroit Medical Center
(DMC) health system in Southeast Michigan, which con-
sists of 2200 inpatient beds. The Institutional Review
Boards of AHMC, DMC and Wayne State University ap-
proved the study prior to its initiation. The study cohort
consisted of hospitalized patients with unique episodes
of bacteremia who met the following inclusion criteria:
bloodstream infections (BSI) caused by either CRE or
ESBL-producing Enterobacteriaceae (monomicrobial iso-
lations), from calendar years 2007–2010, who, on the date
of culture, had severe sepsis, septic shock, or multi-organ
failure. Variables collected for each patient included: 1)
demographics; 2) co-morbidities; 3) recent (3 months) ex-
posures to antibiotics; and 4) recent (3 months) exposures
to various healthcare-associated environments and proce-
dures. Bacteria were identified and susceptibilities were
determined in accordance with Clinical and Laboratory
Standards Institute criteria [10]. Carbapenemase produc-
tion screening was conducted for Enterobacteriacea which
were resistant to one or more third generation cephalo-
sporins and had elevated ertapenem MIC of ≥2 μg/dL,
with the modified Hodge test [10]. ESBL production
was determined automatically and validated with disc
diffusion tests [10]. A clinical prediction score wasdeveloped through construction of a multiple regression
model for predictors of CRE BSI compared to ESBL BSI.
The score was derived from the final model by multiply-
ing the regression coefficients by a factor of 10. Score
performance was assessed by calculation of sensitivity,
specificity, positive predictive value (PPV), negative pre-
dictive value (NPV), and associated 95 % C.I. A receiver
operating characteristic (ROC) curve was generated and
area under the curve (AUC) was tested against a null
AUC of 0.5.
Overall, 343 patients met inclusion criteria, including
285 patients with BSIs due ESBL-producing Enterobacte-
riaceae and 58 patients with BSIs due to CRE. The final
multivariable model of predictors for CRE BSI as com-
pared to ESBL BSI among hospitalized adult patients at
AHMC is displayed in Table 1. Based on this model, a
prediction score was developed (Table 1). The score had
an area under ROC curve (AUC) of 0.75 (CI-95 % 0.69–
0.82) (Fig. 1a). A score of ≥32 to define “high CRE risk”
had sensitivity of 59 % (95 C.I. 45, 71 %), specificity of
76 % (95 C.I. 71, 81 %), PPV of 34 % (95 C.I. 25, 44 %)
and NPV of 90 % (95 C.I. 86, 94 %). Using a cut-point of
32 points or higher to define CRE high risk was then
validated on a cohort of patients from DMC: 166 with
ESBL BSIs and 16 patients with CRE BSIs. The score
had an area under ROC curve of 0.64 (Fig. 1b), sensitiv-
ity of 56 % (95 C.I. 30, 80 %), specificity of 65 % (95 C.I.
57, 72 %), PPV of 13 % (95 C.I. 6, 24 %) and NPV of
94 % (95 C.I. 88, 98 %). In a clinical setting, the score
would thus be calculated by adding the number of points
for each relevant patient condition (Table 1). Patients with
a score less than 32 would be considered low risk for
CRE, as opposed to ESBL.
This study is our first phase in trying to develop a score
that can shorten the time to institution of appropriate
therapy in patients with CRE BSIs, in the hope that even-
tually this would lead to reductions in CRE mortality rates
which are reported to be ~70 % [6]. We know that appro-
priate therapy for CRE infections is delayed by ~5 days
[5], and that delay of instituting appropriate therapy in
severe sepsis is the strongest independent predictor for
mortality [4]. Therefore, apart from improving rapid
diagnostic techniques, among other optional paths, a
prediction score with high performance could theoretic-
ally have a valuable role in such clinical scenarios. How-
ever, clinicians are reluctant to use prediction scores in
their routine clinical practice. The score has to be sim-
ple, based only on parameters that could easily be ex-
tracted while attending the patient and reviewing the
chart bedside. This is our second step in our eventual
goal of developing a scientific reliable CRE BSI score for
adult hospitalized patients [9]. The score was re-developed
using retrospective clinical data from an endemic CRE re-
gion, constituting relatively high numbers. However, some
Table 1 Univariable analyses and multivariable model of carbapenem-resistant Enterobacrteriaceae (CRE) bloodstream infections (BSI)
compared to extended-spectrum β-lactamase producing Enterobacteriaceae (ESBL) BSI: adjusted associations and final score values
Derivation Cohort (AHMC) Validation Cohort (DMC)




OR (95 % CI);
p-value
AOR a (95 % C.I.);
p-value




Male gender 169 (59) 29 (50) 0.69 (0.39, 1.21); 0.19 91 (55) 7 (44)
Age <65 years 47 (17) 16 (28) 1.9 (1.00, 3.71) 0.05 1.8 (0.81, 3.92); 0.16 6 78 (47) 5 (31)
LTCF residencyb 107 (38) 14 (25) 0.53 (0.28, 1.02); 0.06 96 (58) 13 (81)
Recent (3 months) hospitalization
or LTCF stay
241 (85) 45 (78) 0.63 (0.32, 1.27); 0.20 100 (60) 14 (88)
Chronic hemodialysis 15 (5) 4 (7) 1.17 (0.40, 3.40); 0.78 33 (20) 5 (31)
Deteriorated functional status at
admission
223 (79) 37 (67) 0.56 (0.30, 1.06); 0.07 105 (63) 14 (88)
Congestive heart failure 86 (31) 15 (26) 0.80 (0.42, 1.51); 0.48 63 (38) 8 (50)
Diabetes mellitus 115 (40) 22 (38) 0.90 (0.51, 1.61); 0.73 86 (52) 13 (81)
Chronic renal failurec 97 (34) 15 (26) 0.66 (0.35, 1.25); 0.21 68 (41) 10 (63)
No PVDd 218 (77) 50 (86) 1.8 (0.83, 4.07); 0.14 2.7 (1.06, 7.02); 0.04 10 134 (81) 13 (81)
Any neurological disease (including
past cerebral events)
157 (55) 27 (47) 0.7 (0.4, 1.3; 0.2 68 (41) 12 (75)
Past or present (active) malignancy 62 (22) 14 (25) 1.2 (0.6, 2.2; 0.7 32 (19) 2 (13)
Hemiplegia or paraplegia 49 (17) 12 (21) 1.27 (0.63, 2.58); 0.50 25 (15) 7 (44)
Chemotherapy in the past 3 months 7 (2) 6 (10) 4.53 (1.46, 14.0); 0.009 6.8 (1.9–24.7); 0.003 19 5 (3) 1 (6)
Immunosuppressione 51 (18) 17 (29) 1.88 (0.99, 3.57); 0.05 28 (17) 5 (31)
Any use of antibiotics in the preceding
3 months
214 (77) 52 (90) 2.6 (1.1, 6.4); 0.03 112 (68) 14 (88)
Recent (6 months) invasive proceduref 120 (43) 33 (59) 1.9 (1.1, 3.4); 0.03 12 (86) 15 (100)
Intensive care unit stay at infection onset 151 (53) 39 (67) 1.82 (1.00, 3.30); 0.05 67 (40) 10 (63)
Permanent foreign invasive devicesg 145 (52) 44 (77) 3.17 (1.64, 6.15); 0.001 2.5 (1.2–5.2); 0.02 10 115 (70) 13 (81)
Reduced consciousness and/or
cognition at time of acute illness
151 (53) 40 (73) 2.33 (1.23, 4.41); 0.009 2.5 (1.1–5.6); 0.02 9 100 (60) 13 (81)
Severe sepsis / septic shock /
multiorgan failure at culture date
133 (48) 36 (66) 2.1 (1.1, 3.8); 0.02 43 (26) 4 (29)
Length of hospital stay at BSIh
onset >3 days
134 (47) 44 (76) 2.85 (1.49, 5.43); 0.001 1.9 (0.9–4); 0.08 7 61 (37) 11 (73)
aAOR adjusted odds ratio. bLong-term care facility. cSerum creatinine > 1.5 mg% at baseline. dPeripheral Vascular Disease. eImmunosuppression include any one
of the following conditions at illness onset: neutropenia (<500 cells/mm3), glucocorticoid / steroid use in the past month, chemotherapy in the past 3 months,
radiotherapy in the past 3 months, HIV, bone marrow or solid organ transplantation, or anti-TNF-α therapy in past 3 months (e.g. infliximab, adalimumab,
certolizumab pegol, golimumab, etanercept). fInclude any type of surgery, endoscopy, percutaneous intervention. gAn invasive foreign device that was in place
at least 48 h prior to ESBL or CRE isolation. Examples: tracheotomy, any feeding tubes, tunneled central lines, silicon-based urinary catheters, orthopedic external
fixators, implanted defibrillator, pacemaker, and drains of any sort. Prosthetic heart valve or internal prosthetic joints were not considered a permanent foreign
invasive devise. hbloodstream infection.
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of the epidemiology at AHMC. The relative low perfor-
mances of this suggested score, suggest larger cohorts
from various endemic regions should be studied in the
future. The imperfect diagnostics of CRE and ESBL
production can results classification biases and should
prompt consideration.
Some might argue that the clinical dilemma in today’s
era for attending clinicians practicing in tertiary facilities
is a bit broader. For severely septic patients in thehospital setting, instituting early broad spectrum anti-
microbial agents is the common standard of care [3].
For the Gram-negative bacilli (GNB) treatment arm that
should be instituted, practitioners need to choose be-
tween empiric coverage of “only” multidrug resistant
(MDR) GNB isolates (e.g. ESBL-producing Enterobacteria-
ceae, broad-spectrum cephalosporin’s resistant Acinetobac-
ter baumannii and Pseudomonas aeruginosa), as opposed
to empiric coverage for extensively-drug resistant (XDR)
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Fig. 1 a: Receiver Operating Characteristic (ROC) curve of score to predict bloodstream infection (BSI) due to carbapenem-resistant Enterobacteriaceae
(CRE) as opposed to extended-spectrum β-lactamase producing Enterobacteriaceae (ESBL), Assaf Harofeh Medical Center. b: ROC curve of the
score developed at Assaf Harofeh Medical Center to predict bloodstream infection due to CRE as opposed to bloodstream infection due to
ESBL-producing Enterobacteriaceae at Detroit Medical Center
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“CRE score”, which addresses only the Enterobacteriaceae
angle, one might argue that developing a “XDR score”
would be more clinically applicable. We look at this score
as an initial step. Our future goals are to develop and valid-
ate both potential scores prospectively, on larger cohorts of
patients, from distinct geographic locations, where both
MDR and XDR GNBs are endemic in the hospital settings.
This analysis is a crucial and valuable step in our effort to
develop eventually a score with high performances, whichcould lead eventually to reductions in CRE mortality rates,
while avoiding the un-necessary empiric use of broad
spectrum and toxic agents (e.g. polymixins).
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